These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 25355728)

  • 1. MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study.
    Peterfy C; Emery P; Tak PP; Østergaard M; DiCarlo J; Otsa K; Navarro Sarabia F; Pavelka K; Bagnard MA; Gylvin LH; Bernasconi C; Gabriele A
    Ann Rheum Dis; 2016 Jan; 75(1):170-7. PubMed ID: 25355728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significant improvement in synovitis, osteitis, and bone erosion following golimumab and methotrexate combination therapy as compared with methotrexate alone: a magnetic resonance imaging study of 318 methotrexate-naive rheumatoid arthritis patients.
    Østergaard M; Emery P; Conaghan PG; Fleischmann R; Hsia EC; Xu W; Rahman MU
    Arthritis Rheum; 2011 Dec; 63(12):3712-22. PubMed ID: 22127693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: results from the ACT-RAY MRI substudy.
    Conaghan PG; Peterfy C; Olech E; Kaine J; Ridley D; Dicarlo J; Friedman J; Devenport J; Troum O
    Ann Rheum Dis; 2014 May; 73(5):810-6. PubMed ID: 24525910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)).
    Emery P; Deodhar A; Rigby WF; Isaacs JD; Combe B; Racewicz AJ; Latinis K; Abud-Mendoza C; Szczepanski LJ; Roschmann RA; Chen A; Armstrong GK; Douglass W; Tyrrell H
    Ann Rheum Dis; 2010 Sep; 69(9):1629-35. PubMed ID: 20488885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE.
    Tak PP; Rigby W; Rubbert-Roth A; Peterfy C; van Vollenhoven RF; Stohl W; Healy E; Hessey E; Reynard M; Shaw T
    Ann Rheum Dis; 2012 Mar; 71(3):351-7. PubMed ID: 22012969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial.
    Axelsen MB; Eshed I; Hørslev-Petersen K; Stengaard-Pedersen K; Hetland ML; Møller J; Junker P; Pødenphant J; Schlemmer A; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Dam MY; Hansen I; Horn HC; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Krogh NS; Johansen JS; Østergaard M;
    Ann Rheum Dis; 2015 May; 74(5):867-75. PubMed ID: 24412895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques.
    Conaghan PG; Østergaard M; Bowes MA; Wu C; Fuerst T; van der Heijde D; Irazoque-Palazuelos F; Soto-Raices O; Hrycaj P; Xie Z; Zhang R; Wyman BT; Bradley JD; Soma K; Wilkinson B
    Ann Rheum Dis; 2016 Jun; 75(6):1024-33. PubMed ID: 27002108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies.
    Keystone E; Emery P; Peterfy CG; Tak PP; Cohen S; Genovese MC; Dougados M; Burmester GR; Greenwald M; Kvien TK; Williams S; Hagerty D; Cravets MW; Shaw T
    Ann Rheum Dis; 2009 Feb; 68(2):216-21. PubMed ID: 18388156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial.
    Conaghan PG; Durez P; Alten RE; Burmester GR; Tak PP; Klareskog L; Catrina AI; DiCarlo J; Gaillez C; Le Bars M; Zhou X; Peterfy C
    Ann Rheum Dis; 2013 Aug; 72(8):1287-94. PubMed ID: 22915624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate.
    Cohen SB; Keystone E; Genovese MC; Emery P; Peterfy C; Tak PP; Cravets M; Shaw T; Hagerty D
    Ann Rheum Dis; 2010 Jun; 69(6):1158-61. PubMed ID: 20439295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring cartilage loss in the hands and wrists in rheumatoid arthritis with magnetic resonance imaging in a multi-center clinical trial: IMPRESS (NCT00425932).
    Peterfy CG; Olech E; DiCarlo JC; Merrill JT; Countryman PJ; Gaylis NB
    Arthritis Res Ther; 2013 Mar; 15(2):R44. PubMed ID: 23514433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determining MRI Inflammation Targets When Considering a Rheumatoid Arthritis Treat-to-Target Strategy: Results of a Randomized, Placebo-Controlled Trial.
    Ahmad HA; Baker JF; Østergaard M; Ye J; Emery P; Conaghan PG
    Adv Ther; 2019 Sep; 36(9):2384-2393. PubMed ID: 31278695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Magnetic Resonance Imaging (MRI) Results Following Discontinuation of Methotrexate in Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: The COMP-ACT MRI Substudy.
    Peterfy C; Kremer J; Rigby W; Singer N; Birchwood C; Gill D; Reiss W; Pei J; Michalska M
    J Rheumatol; 2020 Mar; 47(3):325-332. PubMed ID: 31154414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.
    Atsumi T; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Yasuda S; Yamanishi Y; Kita Y; Matsubara T; Iwamoto M; Shoji T; Okada T; van der Heijde D; Miyasaka N; Koike T
    Ann Rheum Dis; 2016 Jan; 75(1):75-83. PubMed ID: 26139005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnetic resonance imaging of the hand and wrist in a randomized, double-blind, multicenter, placebo-controlled trial of infliximab for rheumatoid arthritis: Comparison of dynamic contrast enhanced assessments with semi-quantitative scoring.
    Beals C; Baumgartner R; Peterfy C; Balanescu A; Mirea G; Harabagiu A; Popa S; Cheng A; Feng D; Ashton E; DiCarlo J; Vallee MH; Dardzinski BJ
    PLoS One; 2017; 12(12):e0187397. PubMed ID: 29236711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis.
    Peterfy C; DiCarlo J; Emery P; Genovese MC; Keystone EC; Taylor PC; Schlichting DE; Beattie SD; Luchi M; Macias W
    J Rheumatol; 2019 Aug; 46(8):887-895. PubMed ID: 30647190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.
    Emery P; Bingham CO; Burmester GR; Bykerk VP; Furst DE; Mariette X; van der Heijde D; van Vollenhoven R; Arendt C; Mountian I; Purcaru O; Tatla D; VanLunen B; Weinblatt ME
    Ann Rheum Dis; 2017 Jan; 76(1):96-104. PubMed ID: 27165179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.
    Keystone EC; Kavanaugh AF; Sharp JT; Tannenbaum H; Hua Y; Teoh LS; Fischkoff SA; Chartash EK
    Arthritis Rheum; 2004 May; 50(5):1400-11. PubMed ID: 15146409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial.
    Conaghan PG; Emery P; Østergaard M; Keystone EC; Genovese MC; Hsia EC; Xu W; Rahman MU
    Ann Rheum Dis; 2011 Nov; 70(11):1968-74. PubMed ID: 21784729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MRI assessment of early response to certolizumab pegol in rheumatoid arthritis: a randomised, double-blind, placebo-controlled phase IIIb study applying MRI at weeks 0, 1, 2, 4, 8 and 16.
    Østergaard M; Jacobsson LT; Schaufelberger C; Hansen MS; Bijlsma JW; Dudek A; Rell-Bakalarska M; Staelens F; Haake R; Sundman-Engberg B; Bliddal H
    Ann Rheum Dis; 2015 Jun; 74(6):1156-63. PubMed ID: 25512675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.